Tofacitinib in Ulcerative Colitis: Beyond Biologics?

被引：0
|
作者：
Anirvan, Prajna [1 ]
Giri, Suprabhat [2 ]
机构：
[1] Kalinga Gastroenterol Fdn, Cuttack, India
[2] Kalinga Inst Med Sci, Dept Gastroenterol & Hepatol, Bhubaneswar 751024, Odisha, India
来源：
INFLAMMATORY BOWEL DISEASES | 2024年 / 30卷 / 03期
关键词：
D O I：
10.1093/ibd/izad308
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：515 / 515
页数：1
相关论文
共 50 条
  • [41] The role and prospect of tofacitinib in patients with ulcerative colitis
    Lee, Jun
    INTESTINAL RESEARCH, 2022,
  • [42] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
    Sands, Bruce E.
    Taub, Pam R.
    Feagan, Brian G.
    Armuzzi, Alessandro
    Friedman, Gary S.
    Moscariello, Michele
    Lawendy, Nervin
    Pedersen, Ronald D.
    Chan, Gary
    Nduaka, Chudy I.
    Quirk, Daniel
    Salese, Leonardo
    Su, Chinyu
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S380
  • [43] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Friedman, G. S.
    Moscariello, M.
    Lawendy, N.
    Pedersen, R. D.
    Chan, G.
    Nduaka, C. I.
    Quirk, D.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S23 - S23
  • [44] Stringent criteria for withdrawal of biologics in ulcerative colitis
    Tan, Malcolm
    Ng, Valerie
    Lim, Chong Teik
    Leow, Wei-Qiang
    Chan, Webber
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 687 - 687
  • [45] Stringent criteria for withdrawal of biologics in ulcerative colitis
    Tan, Malcolm
    Ng, Valerie
    Lim, Chong Teik
    Leow, Wei-Qiang
    Chan, Webber
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 6 (09): : 687 - 688
  • [46] The impact of biologics in surgical outcomes in ulcerative colitis
    Argollo, Marjorie C.
    Kotze, Paulo Gustavo
    Spinelli, Antonino
    Gomes, Tarcia N. F.
    Danese, Silvio
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2018, 32-33 : 79 - 87
  • [47] Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis
    Arivarasan, K.
    Bhardwaj, Vaishali
    Sud, Sukrit
    Sachdeva, Sanjeev
    Puri, Amarender Singh
    INTESTINAL RESEARCH, 2016, 14 (04) : 365 - 368
  • [48] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Damiao, A. O.
    Lawendy, N.
    Solano, G.
    Kwok, K.
    Woolcott, J.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S557 - S558
  • [49] Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational study
    Dragoni, G.
    Innocenti, T.
    Amiot, A.
    Castiglione, F.
    Melotti, L.
    Festa, S.
    Savarino, E. V.
    Truyens, M.
    Argyriou, K.
    Noviello, D.
    Molnar, T.
    Bouillon, V.
    Bezzio, C.
    Eder, P.
    Fernandes, S.
    Kagramanova, A.
    Armuzzi, A.
    Oliveira, R.
    Viola, A.
    Ribaldone, D. G.
    Drygiannakis, I.
    Vigano, C.
    Calella, F.
    Gravina, A. G.
    Pugliese, D.
    Chaparro, M.
    Ellul, P.
    Vieujean, S.
    Milla, M.
    Caprioli, F.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I998 - I999
  • [50] Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
    Winthrop, Kevin L.
    Loftus, Edward V. Jr Jr
    Baumgart, Daniel C.
    Reinisch, Walter
    Nduaka, Chudy, I
    Lawendy, Nervin
    Chan, Gary
    Mundayat, Rajiv
    Friedman, Gary S.
    Salese, Leonardo
    Thorpe, Andrew J.
    Su, Chinyu
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (06): : 914 - 929
12345